export default function BremelanotideOverviewPanel() {
  return (
    <div className="reta-overview">

      <p className="reta-overview__opener">
        Bremelanotide &mdash; sold as Vyleesi, known in the community as PT-141 &mdash; is a drug that targets sexual desire by acting on brain circuits involved in motivation and arousal, not by changing hormone levels or improving blood flow. It holds FDA approval for low sexual desire in premenopausal women. Men use it widely off-label through community channels. The clinical results in the approved population are real but modest, nausea affects roughly 40% of users, and blood pressure rises with every dose &mdash; which is a genuine contraindication for some people.
      </p>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 1</div>
        <h3 className="reta-overview__profile-heading">The Average Person &mdash; a woman with low desire looking for something that actually helps</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I have almost no interest in sex and it&rsquo;s affecting my relationship. I heard there&rsquo;s an FDA-approved drug for this in women &mdash; is it real, does it actually work, and what&rsquo;s the catch?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It targets desire specifically, not just arousal</strong><br />Most sexual function medications work on blood flow &mdash; which helps with physical arousal but doesn&rsquo;t address the brain-level experience of wanting sex. Bremelanotide works differently: it acts on brain pathways that are involved in wanting and motivation. For women with hypoactive sexual desire disorder &mdash; where the primary complaint is low desire, not physical function &mdash; this mechanism actually addresses what&rsquo;s wrong rather than working around it.</li>
          <li><strong>The FDA approval is based on real trial data</strong><br />The Phase III trials (RECONNECT program) showed statistically significant improvements in sexual desire and reduction in distress related to low desire compared to placebo. The effects were real in the data, even if the magnitude was modest. For a condition that previously had only one other approved drug (flibanserin, which has an alcohol interaction warning that limits practical use), having a second option matters.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The trial results were statistically significant but clinically modest &mdash; meaningful improvements in standardized desire scores but not dramatic transformation. Nausea is the main obstacle: it occurs in roughly 40% of people and peaks in the first few hours after injection, lasting up to 12 hours. Some people find this manageable; others stop because of it. Blood pressure rises transiently with each dose &mdash; a real concern if you have hypertension. The drug is used on-demand (injected before anticipated sexual activity), not daily. Net: a real drug with real effects and real side effects; the nausea and blood pressure issues determine whether it&rsquo;s practically tolerable for you specifically.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 2</div>
        <h3 className="reta-overview__profile-heading">The Athlete &mdash; using PT-141 for libido improvement alongside a performance stack</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I&rsquo;ve heard PT-141 is popular in the peptide community for both men and women as a libido compound. What does it actually do and is the off-label use in men reasonable?&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>It works on a fundamentally different pathway than anything else in a typical stack</strong><br />Most compounds athletes use affect muscle, fat, recovery, or hormones. Bremelanotide operates on a completely separate brain system &mdash; the melanocortin pathway involved in desire and arousal. It can produce noticeably enhanced sexual motivation within 45-90 minutes of injection. For men, the experience is often described as desire amplification, not just physical function change &mdash; which is distinct from what, say, tadalafil provides.</li>
          <li><strong>The off-label use in men has a plausible mechanistic basis</strong><br />The melanocortin system is present and functional in both sexes. Early phase trials of bremelanotide&rsquo;s predecessor compound included men. The mechanism of action doesn&rsquo;t change based on sex. The absence of a formal male indication is a regulatory gap, not a sign that the biology doesn&rsquo;t apply &mdash; though it does mean there&rsquo;s less controlled trial data specifically in men.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">Community PT-141 is sourced gray-market, not pharmaceutical-grade. The nausea profile that occurs in 40% of trial participants doesn&rsquo;t disappear in the off-label setting. Blood pressure elevation is a real physiological effect that occurs regardless of whether you have a prescription. Stacking bremelanotide with tadalafil or other vasoactive compounds combines a blood-pressure-raising drug with a blood-pressure-lowering one &mdash; the interaction pharmacology is not well characterized and shouldn&rsquo;t be assumed safe. Repeated use causes focal hyperpigmentation of skin &mdash; this is a documented long-term effect, not a theoretical concern. Net: on-demand libido enhancement is the real use case, but sourcing quality, nausea management, and blood pressure awareness are genuine management considerations.</p>
      </div>

      <div className="reta-overview__profile">
        <div className="reta-overview__profile-label">Profile 3</div>
        <h3 className="reta-overview__profile-heading">The Biohacker &mdash; mapping melanocortin receptor pharmacology and optimizing dose/timing</h3>
        <blockquote className="reta-overview__profile-think">&ldquo;I want to understand the melanocortin receptor subtype pharmacology &mdash; MC3R vs. MC4R, central vs. peripheral effects &mdash; and whether there&rsquo;s a dosing approach that maximizes the desire signal while minimizing nausea.&rdquo;</blockquote>
        <p className="reta-overview__profile-why-heading">Why they&rsquo;re excited</p>
        <ol className="reta-overview__profile-why">
          <li><strong>The receptor subtype biology is genuinely interesting</strong><br />Bremelanotide acts on both MC3R and MC4R in the central nervous system. MC4R specifically is associated with sexual behavior, appetite regulation, and energy homeostasis. The melanocortin system sits at an intersection of motivation, appetite, and social behavior that is pharmacologically underexplored. The fact that the same receptor system that drives sexual desire also regulates feeding and energy balance creates interesting crosstalk questions for biohackers thinking about behavioral optimization.</li>
          <li><strong>The hyperpigmentation effect maps the mechanism</strong><br />The skin darkening that occurs with repeated bremelanotide use is not a mystery &mdash; it&rsquo;s the MC1R receptor in melanocytes responding to systemic melanocortin receptor agonism. Understanding that bremelanotide hits multiple melanocortin receptor subtypes simultaneously helps explain why the drug has this off-target effect. For a biohacker, tracking focal pigmentation changes is a real biomarker of cumulative MC1R activation.</li>
        </ol>
        <p className="reta-overview__profile-check-heading">Reality check</p>
        <p className="reta-overview__profile-check">The nausea is mediated by area postrema melanocortin receptors &mdash; meaning it&rsquo;s an on-target central effect, not an off-target peripheral side effect that can be engineered away at the receptor level. Lower doses reduce nausea but also reduce the desire signal; there is no clean separation in the current dose range. The hyperpigmentation is cumulative and not rapidly reversible &mdash; this is a direct MC1R effect that accumulates with use and cannot be offset by cycling. Blood pressure elevation appears to be a peripheral vasoconstrictive effect of melanocortin agonism, distinct from the central desire pathway &mdash; again, on-target rather than a formulation artifact that better sourcing would eliminate. Net: the mechanism depth is real, but the side effects map directly to the same mechanisms as the desired effect &mdash; they cannot be optimized away without blunting efficacy.</p>
      </div>

      <div className="reta-overview__bottom">
        <p className="reta-overview__bottom-heading">The honest bottom line</p>
        <div className="reta-overview__bottom-cols">
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What Bremelanotide is NOT</p>
            <ul className="reta-overview__bottom-list">
              <li>A hormone &mdash; it does not raise testosterone or estrogen; it acts on brain desire circuits</li>
              <li>An erectile function drug &mdash; it targets desire, not blood flow; different problem than PDE5 inhibitors address</li>
              <li>Free of cardiovascular risk &mdash; blood pressure rises with every dose, which is a real contraindication for hypertension</li>
              <li>Permanently pigment-safe with repeated use &mdash; focal hyperpigmentation is a documented long-term effect</li>
              <li>Proven effective in men by controlled trial data &mdash; the male indication is off-label extrapolation</li>
              <li>A daily medication &mdash; it is on-demand, injected before anticipated activity</li>
            </ul>
          </div>
          <div className="reta-overview__bottom-col">
            <p className="reta-overview__bottom-col-heading">What makes it interesting</p>
            <ul className="reta-overview__bottom-list">
              <li>The only on-demand drug targeting brain-level sexual desire &mdash; genuinely different mechanism from everything else</li>
              <li>FDA-approved for HSDD in premenopausal women &mdash; a real indication based on real controlled trial data</li>
              <li>Works within 45-90 minutes, not days &mdash; the on-demand profile is clinically useful</li>
              <li>The melanocortin biology connects desire, appetite, and pigmentation through a pharmacologically coherent mechanism</li>
            </ul>
          </div>
        </div>
      </div>

    </div>
  );
}
